Topic

Pennsylvania

A collection of 524 issues

How to Get Rylaze Approved by Cigna in Pennsylvania: Prior Authorization Forms, Appeal Process, and Medical Necessity Requirements

Answer Box: Getting Rylaze Covered by Cigna in Pennsylvania Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn) requires prior authorization from Cigna in Pennsylvania. The fastest path to approval: submit Cigna's Rylaze PA form with documented E. coli asparaginase hypersensitivity, ALL/LBL diagnosis, and oncologist prescription. Standard approval takes 72
5 min read

Getting Kineret (Anakinra) Covered by Humana in Pennsylvania: Prior Authorization, Appeals, and Medical Necessity Requirements

Quick Answer: Your Path to Kineret Coverage Humana requires prior authorization for Kineret (anakinra) with step therapy requirements. In Pennsylvania, you have strong appeal rights—about 50% of external reviews overturn denials. First step today: Contact your prescriber to gather documentation of failed DMARD/TNF inhibitor trials and current disease
6 min read

The Requirements Checklist to Get Retevmo (selpercatinib) Covered by UnitedHealthcare in Pennsylvania

Answer Box: Fast Track to Approval To get Retevmo (selpercatinib) covered by UnitedHealthcare in Pennsylvania: 1) Confirm RET fusion-positive status with FDA-approved testing (FoundationOne CDx preferred), 2) Submit prior authorization through UnitedHealthcare provider portal with complete molecular pathology reports and clinical documentation, 3) If denied, file internal appeal within 6
5 min read

How to Get Raxone (Idebenone) Covered by UnitedHealthcare in Pennsylvania: Prior Authorization, Appeals & Cost-Saving Strategies

Quick Answer: Raxone (idebenone) is not FDA-approved in the U.S., making UnitedHealthcare coverage extremely difficult. However, you can pursue coverage through: (1) Prior authorization with medical necessity documentation for off-label use, (2) Step therapy exceptions if alternatives failed, and (3) Pennsylvania's external review process, which overturns ~50%
6 min read